Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Phase 2 Completed 35 enrolled French National Agency for Research on AIDS and Viral Hepatitis Bristol-Myers Squibb · collab Gilead Sciences · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

the trial assessed the pharmacokinetics and long term plasma exposure of the following antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination. All drugs will be delivered in MEMS electronic device to monitor dosing history.

Timeline

Start: 2008-01
Primary completion: 2008-11
Completion: 2008-11

Publications

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentre F, Goujard C. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013 May;57(5):2265-71. doi: 10.1128/AAC.02605-12. Epub 2013 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atazanavir	Other / unclassified	2 unknown	—
Subject	Ritonavir	Other / unclassified	1 unknown	—
Subject	Tenofovir/emtricitabine	Unknown	1 unknown	—

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Summary

Timeline

Publications

Drugs

Indications